CN107709324A - 黄嘌呤衍生物 - Google Patents

黄嘌呤衍生物 Download PDF

Info

Publication number
CN107709324A
CN107709324A CN201680031442.XA CN201680031442A CN107709324A CN 107709324 A CN107709324 A CN 107709324A CN 201680031442 A CN201680031442 A CN 201680031442A CN 107709324 A CN107709324 A CN 107709324A
Authority
CN
China
Prior art keywords
acid
pharmaceutically acceptable
solvate
methyl
xanthine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201680031442.XA
Other languages
English (en)
Other versions
CN107709324B (zh
Inventor
高愚哲
王国成
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Tasly Diyi Pharmaceutical Co Ltd
Original Assignee
Jiangsu Tasly Diyi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Tasly Diyi Pharmaceutical Co Ltd filed Critical Jiangsu Tasly Diyi Pharmaceutical Co Ltd
Publication of CN107709324A publication Critical patent/CN107709324A/zh
Application granted granted Critical
Publication of CN107709324B publication Critical patent/CN107709324B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及一种如式I所示的黄嘌呤衍生物，其中，R选自：R1选自氰基或甲氧羰基；R2选自氢、卤素原子，直链或支链的被1~5个卤素原子取代或未被取代的C1‑6烷基、直链或支链的被1~5个卤素原子取代或未被取代的C1‑6烷氧基；X、Y分别独立的选自C或N；n为0、1、2、3或4。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201680031442.XA 2015-05-29 2016-05-26 黄嘌呤衍生物 Active CN107709324B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510290336 2015-05-29
CN2015102903360 2015-05-29
PCT/CN2016/083406 WO2016192559A1 (zh) 2015-05-29 2016-05-26 黄嘌呤衍生物

Publications (2)

Publication Number Publication Date
CN107709324A true CN107709324A (zh) 2018-02-16
CN107709324B CN107709324B (zh) 2021-06-08

Family

ID=57440191

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610356576.0A Active CN106188058B (zh) 2015-05-29 2016-05-25 黄嘌呤衍生物
CN201680031442.XA Active CN107709324B (zh) 2015-05-29 2016-05-26 黄嘌呤衍生物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201610356576.0A Active CN106188058B (zh) 2015-05-29 2016-05-25 黄嘌呤衍生物

Country Status (15)

Country Link
US (1) US10358449B2 (zh)
EP (1) EP3305787B1 (zh)
JP (1) JP6742345B2 (zh)
KR (1) KR20180011270A (zh)
CN (2) CN106188058B (zh)
AU (1) AU2016270100B2 (zh)
CA (1) CA2987697A1 (zh)
ES (1) ES2908658T3 (zh)
HK (1) HK1245796A1 (zh)
IL (1) IL255829B (zh)
MY (1) MY186396A (zh)
RU (1) RU2709348C2 (zh)
SG (1) SG11201709782SA (zh)
TW (1) TWI682931B (zh)
WO (1) WO2016192559A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105983016B (zh) 2015-03-23 2023-08-11 天士力医药集团股份有限公司 一种含有水飞蓟宾的药物组合

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1980930A (zh) * 2004-02-18 2007-06-13 贝林格尔·英格海姆国际有限公司 8－[3－氨基－哌啶－1－基]－黄嘌呤,其制备及dpp－ⅳ抑制剂形式的用途
CN102186466A (zh) * 2008-10-16 2011-09-14 贝林格尔.英格海姆国际有限公司 对尽管使用口服或非口服抗糖尿病药物治疗但血糖控制仍不足的患者中的糖尿病的治疗
CN102199151A (zh) * 2004-02-18 2011-09-28 贝林格尔.英格海姆国际有限公司 8-[3-氨基-哌啶-1-基]-黄嘌呤、制备及用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6110949A (en) 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
ATE409466T1 (de) * 2002-01-11 2008-10-15 Novo Nordisk As Verfahren und zusammensetzung zur behandlung von diabetes, hypertonie, chronischer herzinsuffizienz und mit flüssigkeitsretention einhergehenden zuständen
US7482337B2 (en) * 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) * 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) * 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
EA031225B1 (ru) * 2008-08-15 2018-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы дпп-4 для заживления ран
CN103172633B (zh) * 2011-12-22 2016-08-03 成都地奥制药集团有限公司 一种化合物及其制备方法和用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1980930A (zh) * 2004-02-18 2007-06-13 贝林格尔·英格海姆国际有限公司 8－[3－氨基－哌啶－1－基]－黄嘌呤,其制备及dpp－ⅳ抑制剂形式的用途
CN102199151A (zh) * 2004-02-18 2011-09-28 贝林格尔.英格海姆国际有限公司 8-[3-氨基-哌啶-1-基]-黄嘌呤、制备及用途
CN102186466A (zh) * 2008-10-16 2011-09-14 贝林格尔.英格海姆国际有限公司 对尽管使用口服或非口服抗糖尿病药物治疗但血糖控制仍不足的患者中的糖尿病的治疗

Also Published As

Publication number Publication date
CN107709324B (zh) 2021-06-08
US10358449B2 (en) 2019-07-23
CA2987697A1 (en) 2016-12-08
HK1245796A1 (zh) 2018-08-31
WO2016192559A1 (zh) 2016-12-08
US20180162860A1 (en) 2018-06-14
MY186396A (en) 2021-07-22
RU2709348C2 (ru) 2019-12-18
EP3305787A1 (en) 2018-04-11
JP6742345B2 (ja) 2020-08-19
EP3305787B1 (en) 2022-02-16
TW201643166A (zh) 2016-12-16
CN106188058A (zh) 2016-12-07
CN106188058B (zh) 2020-11-06
TWI682931B (zh) 2020-01-21
EP3305787A4 (en) 2018-11-21
RU2017145919A (ru) 2019-07-02
SG11201709782SA (en) 2017-12-28
JP2018520120A (ja) 2018-07-26
IL255829A (en) 2018-01-31
RU2017145919A3 (zh) 2019-08-09
AU2016270100A1 (en) 2017-12-14
KR20180011270A (ko) 2018-01-31
IL255829B (en) 2021-02-28
AU2016270100B2 (en) 2020-02-13
ES2908658T3 (es) 2022-05-03

Similar Documents

Publication Publication Date Title
WO2017162108A1 (zh) 一种柱芳烃类复合物、其制备方法、药物组合物和用途
TW201026676A (en) A method of inhibiting hepatitis C virus by combination of a 5,6-dihydro-1H-pyridin-2-one and one or more additional antiviral compounds
EP2786998B1 (en) Thienyl [3, 2-d]pyrimidin-4-one compounds, preparation method, pharmaceutical compositions and use thereof
US20080075666A1 (en) Methods and compositions for treating diastolic dysfunction
CN103038232A (zh) 单独的和与PDE5抑制剂相组合的sGC刺激剂、sGC活化剂用于治疗系统性硬化症(SSc)的用途
JP2023096079A (ja) 化合物の製剤およびそれらの使用
TW202023563A (zh) 新穎喹唑啉egfr抑制劑
CN109563088A (zh) MEK/PI3K和mTOR/MEK/PI3K生物途径的多功能抑制剂和使用多功能抑制剂的治疗方法
US9562046B2 (en) Means and method for treating solid tumors
US20220089599A1 (en) Alkynyl nicotinamide compounds as kinase inhibitors
CN107709324A (zh) 黄嘌呤衍生物
CN108017656B (zh) 喜树碱衍生物及其在制备抗肿瘤药物中的应用
CN101550135A (zh) As-605240的制备方法及在制备治疗炎性疾病药物中的应用
JP2022524243A (ja) ニコランジル誘導体
RU2549441C2 (ru) Способы и фармацевтические композиции для лечения синдрома дауна
CN103183722B (zh) 一种乙二醛酶i抑制剂及其制备方法和医药用途
US20230218563A1 (en) Methods for treating or preventing chronic kidney disease
CN105636956B (zh) 作为细胞坏死阻碍剂的吲哚化合物
CN112457291B (zh) 苯并硫代吡喃酮类化合物的盐及其制备方法和用途
CN114805141A (zh) 4-胍基苯甲酸芳基酯类化合物及其在抗SARS-CoV-2病毒中的用途
WO2002041891A2 (en) Hiv treatment with benzimidazoles
WO2007094193A1 (ja) 血管新生阻害剤及び血管新生を伴う疾病に対する予防又は治療剤並びに食品
CN112826821B (zh) 别嘌呤醇类衍生物在制备预防和/或治疗糖尿病的药物中的用途
WO2023123008A1 (zh) 一种双胍衍生物及其应用
US9737510B2 (en) Indazole compounds and a process for the preparation thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant